跳轉至內容
Merck
  • Preparation and in vitro antimicrobial activity of silver-bearing degradable polymeric nanoparticles of polyphosphoester-block-poly(L-lactide).

Preparation and in vitro antimicrobial activity of silver-bearing degradable polymeric nanoparticles of polyphosphoester-block-poly(L-lactide).

ACS nano (2015-01-27)
Young H Lim, Kristin M Tiemann, Gyu Seong Heo, Patrick O Wagers, Yohannes H Rezenom, Shiyi Zhang, Fuwu Zhang, Wiley J Youngs, David A Hunstad, Karen L Wooley
摘要

The development of well-defined polymeric nanoparticles (NPs) as delivery carriers for antimicrobials targeting human infectious diseases requires rational design of the polymer template, an efficient synthetic approach, and fundamental understanding of the developed NPs, e.g., drug loading/release, particle stability, and other characteristics. Herein, we developed and evaluated the in vitro antimicrobial activity of silver-bearing, fully biodegradable and functional polymeric NPs. A series of degradable polymeric nanoparticles (dNPs), composed of phosphoester and L-lactide and designed specifically for silver loading into the hydrophilic shell and/or the hydrophobic core, were prepared as potential delivery carriers for three different types of silver-based antimicrobials-silver acetate or one of two silver carbene complexes (SCCs). Silver-loading capacities of the dNPs were not influenced by the hydrophilic block chain length, loading site (i.e., core or shell), or type of silver compound, but optimization of the silver feed ratio was crucial to maximize the silver loading capacity of dNPs, up to ca. 12% (w/w). The release kinetics of silver-bearing dNPs revealed 50% release at ca. 2.5-5.5 h depending on the type of silver compound. In addition, we undertook a comprehensive evaluation of the rates of hydrolytic or enzymatic degradability and performed structural characterization of the degradation products. Interestingly, packaging of the SCCs in the dNP-based delivery system improved minimum inhibitory concentrations up to 70%, compared with the SCCs alone, as measured in vitro against 10 contemporary epidemic strains of Staphylococcus aureus and eight uropathogenic strains of Escherichia coli. We conclude that these dNP-based delivery systems may be beneficial for direct epithelial treatment and/or prevention of ubiquitous bacterial infections, including those of the skin and urinary tract.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
二甲基亚砜, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
二甲基亚砜, ACS reagent, ≥99.9%
Sigma-Aldrich
二甲基亚砜, for molecular biology
Sigma-Aldrich
硝酸, ACS reagent, 70%
Sigma-Aldrich
二甲基亚砜, suitable for HPLC, ≥99.7%
Sigma-Aldrich
二甲基亚砜, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
二甲基亚砜, ReagentPlus®, ≥99.5%
Sigma-Aldrich
乙酸铵, ACS reagent, ≥97%
Sigma-Aldrich
二甲基亚砜, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
3-吗啉丙磺酸, ≥99.5% (titration)
Sigma-Aldrich
二甲基亚砜, anhydrous, ≥99.9%
Sigma-Aldrich
硝酸, 70%, purified by redistillation, ≥99.999% trace metals basis
Sigma-Aldrich
二甲基亚砜, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
乙酸铵, ≥99.99% trace metals basis
Sigma-Aldrich
苯甲醇, ReagentPlus®, ≥99%
Sigma-Aldrich
苯甲醇, ACS reagent, ≥99.0%
Sigma-Aldrich
1,8-二氮杂双环[5.4.0]十一碳-7-烯, 98%
Sigma-Aldrich
三乙基胺, ≥99.5%
Sigma-Aldrich
硝酸, puriss. p.a., reag. ISO, reag. Ph. Eur., for determinations with dithizone, ≥65%
Sigma-Aldrich
硝酸, puriss. p.a., 65.0-67.0%
Sigma-Aldrich
3-吗啉丙磺酸, BioPerformance Certified, suitable for cell culture, ≥99.5% (titration)
Supelco
乙酸铵, LiChropur, eluent additive for LC-MS
Sigma-Aldrich
二甲基亚砜, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
乙酸铵, for molecular biology, ≥98%
Sigma-Aldrich
三乙基胺, BioUltra, ≥99.5% (GC)
Supelco
苯甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
三乙基胺, ≥99%
Sigma-Aldrich
乙酸铵 溶液, for molecular biology, 7.5 M
USP
苯甲醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
2,2-二甲氧基-苯基苯乙酮, 99%